VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: chirodoc who wrote (2030)	8/18/1997 2:50:00 AM
From: T. Mann	of 9719

<<have you seen the info on lydek? seems they have a herpes topical almost ready for market and a fairly interesting pipeline>> This is the fourth Phase III trial for n-docosanol. The previous three large trials have failed to demonstrate efficacy (time to healing). This one shows statistically significant reduction of the healing times versus placebo, albeit very marginal one (p*0.035). I suspect that if you give a placebo to the large number of patients, 1 trial out of 4 should show some statistical significance. In short, IMHO the FDA aproval is not assured and LDAKA's drug may be further from the market than it looks. T.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next